Identification of transaldolase as a novel serum biomarker for hepatocellular carcinoma metastasis using xenografted mouse model and clinic samples

Cancer Letters

Volumn 313, Issue 2, 2011, Pages 154-166

  Wang, Cun ^a   Guo, Kun ^a   Gao, Dongmei ^a   Kang, Xiaonan ^a   Jiang, Kai ^a   Li, Yan ^a   Sun, Lu ^a   Zhang, Shu ^a   Sun, Chun ^a   Liu, Xiaohui ^a   Wu, Weizhong ^a   Yang, Pengyuan ^a   Liu, Yinkun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; ITRAQ; Metastasis; Transaldolase

Indexed keywords

TRANSALDOLASE;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTITATION; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TUMOR XENOGRAFT; TWO DIMENSIONAL LIQUID CHROMATOGRAPHY; UNINDEXED SEQUENCE; VALIDATION PROCESS; WESTERN BLOTTING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; PREDICTIVE VALUE OF TESTS; PROTEOME; SENSITIVITY AND SPECIFICITY; SERUM; TRANSALDOLASE; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 82655187422     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.031     Document Type: Article

References (41)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA. Cancer J. Clin. 2002, 55(2005):74-108.
2. Bai D.S., Dai Z., Zhou J., Liu Y.K., Qiu S.J., Tan C.J., Shi Y.H., Huang C., Wang Z., He Y.F., Fan J. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology 2009, 49:460-470.
3. Yang M.H., Chen C.L., Chau G.Y., Chiou S.H., Su C.W., Chou T.Y., Peng W.L., Wu J.C. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009, 50:1464-1474.
4. Tang D.J., Dong S.S., Ma N.F., Xie D., Chen L., Fu L., Lau S.H., Li Y., Li Y., Guan X.Y. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology 2010, 51:1255-1263.
5. Fu J., Chen Y., Cao J., Luo T., Qian Y.W., Yang W., Ren Y.B., Su B., Cao G.W., Yang Y., Yan Y.Q., Shen F., Wu M.C., Feng G.S., Wang H.Y. P28(GANK) overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology 2010, 53:181-192.
6. Zhao Y., Lee W.N., Xiao G.G. Quantitative proteomics and biomarker discovery in human cancer. Expert Rev. Proteomics 2009, 6:115-118.
7. Pang J., Liu W.P., Liu X.P., Li L.Y., Fang Y.Q., Sun Q.P., Liu S.J., Li M.T., Su Z.L., Gao X. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J. Proteome Res. 2010, 9:216-226.
8. Zhao L., Liu Y., Sun X., Peng K., Ding Y. Serum proteome analysis for profiling protein markers associated with lymph node metastasis in colorectal carcinoma. J. Comp. Pathol. 2011, 144:187-194.
9. Xue H., Lu B., Zhang J., Wu M., Huang Q., Wu Q., Sheng H., Wu D., Hu J., Lai M. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J. Proteome Res. 2010, 9:545-555.
10. Yu B., Li S.Y., An P., Zhang Y.N., Liang Z.J., Yuan S.J., Cai H.Y. Comparative study of proteome between primary cancer and hepatic metastatic tumor in colorectal cancer. World J. Gastroenterol. 2004, 10:2652-2656.
11. Yu Y., Shen H., Yu H., Zhong F., Zhang Y., Zhang C., Zhao J., Li H., Chen J., Liu Y., Yang P. Systematic proteomic analysis of human hepotacellular carcinoma cells reveals molecular pathways and networks involved in metastasis. Mol. Biosyst. 2011, 7:1908-1916.
12. Choong L.Y., Lim S., Chong P.K., Wong C.Y., Shah N., Lim Y.P. Proteome-wide profiling of the MCF10AT breast cancer progression model. PLoS One 2010, 5:e11030.
13. Cui J.F., Liu Y.K., Zhang L.J., Shen H.L., Song H.Y., Dai Z., Yu Y.L., Zhang Y., Sun R.X., Chen J., Tang Z.Y., Yang P.Y. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis in vitro. Proteomics 2006, 6:5953-5961.
14. Hung K.E., Yu K.H. Proteomic approaches to cancer biomarkers. Gastroenterology 2010, 138:46-51.
15. Ritorto M.S., Borlak J. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies. J. Proteome Res. 2011.
16. Liu Y., Li C., Xing Z., Yuan X., Wu Y., Xu M., Tu K., Li Q., Wu C., Zhao M., Zeng R. Proteomic mining in the dysplastic liver of WHV/c-myc mice-insights and indicators for early hepatocarcinogenesis. FEBS. J. 2010, 277:4039-4053.
17. Orazine C.I., Hincapie M., Hancock W.S., Hattersley M., Hanke J.H. A proteomic analysis of the plasma glycoproteins of a MCF-7 mouse xenograft: a model system for the detection of tumor markers. J. Proteome Res. 2008, 7:1542-1554.
18. Whiteaker J.R., Zhang H., Zhao L., Wang P., Kelly-Spratt K.S., Ivey R.G., Piening B.D., Feng L.C., Kasarda E., Gurley K.E., Eng J.K., Chodosh L.A., Kemp C.J., McIntosh M.W., Paulovich A.G. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J. Proteome Res. 2007, 6:3962-3975.
19. Rantalainen M., Cloarec O., Beckonert O., Wilson I.D., Jackson D., Tonge R., Rowlinson R., Rayner S., Nickson J., Wilkinson R.W., Mills J.D., Trygg J., Nicholson J.K., Holmes E. Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. J. Proteome Res. 2006, 5:2642-2655.
20. Cima I., Schiess R., Wild P., Kaelin M., Schuffler P., Lange V., Picotti P., Ossola R., Templeton A., Schubert O., Fuchs T., Leippold T., Wyler S., Zehetner J., Jochum W., Buhmann J., Cerny T., Moch H., Gillessen S., Aebersold R., Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3342-3347.
21. Van den Bemd G.J., Krijgsveld J., Luider T.M., van Rijswijk A.L., Demmers J.A., Jenster G. Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol. Cell Proteomics 2006, 5:1830-1839.
22. Wu C.C., Peng P.H., Chang Y.T., Huang Y.S., Chang K.P., Hao S.P., Tsang N.M., Yeh C.T., Chang Y.S., Yu J.S. Identification of potential serum markers for nasopharyngeal carcinoma from a xenografted mouse model using Cy-dye labeling combined with three-dimensional fractionation. Proteomics 2008, 8:3605-3620.
23. Wei B.R., Hoover S.B., Ross M.M., Zhou W., Meani F., Edwards J.B., Spehalski E.I., Risinger J.I., Alvord W.G., Quinones O.A., Belluco C., Martella L., Campagnutta E., Ravaggi A., Dai R.M., Goldsmith P.K., Woolard K.D., Pecorelli S., Liotta L.A., Petricoin E.F., Simpson R.M. Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS One 2009, 4:e7670.
24. Pitteri S.J., JeBailey L., Faca V.M., Thorpe J.D., Silva M.A., Ireton R.C., Horton M.B., Wang H., Pruitt L.C., Zhang Q., Cheng K.H., Urban N., Hanash S.M., Dinulescu D.M. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One 2009, 4:e7916.
25. Faca V.M., Song K.S., Wang H., Zhang Q., Krasnoselsky A.L., Newcomb L.F., Plentz R.R., Gurumurthy S., Redston M.S., Pitteri S.J., Pereira-Faca S.R., Ireton R.C., Katayama H., Glukhova V., Phanstiel D., Brenner D.E., Anderson M.A., Misek D., Scholler N., Urban N.D., Barnett M.J., Edelstein C., Goodman G.E., Thornquist M.D., McIntosh M.W., DePinho R.A., Bardeesy N., Hanash S.M. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 2008, 5:e123.
26. Chong P.K., Lee H., Zhou J., Liu S.C., Loh M.C., So J.B., Lim K.H., Yeoh K.G., Lim Y.P. Reduced plasma APOA1 level is associated with gastric tumor growth in MKN45 mouse xenograft model. J. Proteomics 2010, 73:1632-1640.
27. Chong P.K., Lee H., Zhou J., Liu S.C., Loh M.C., Wang T.T., Chan S.P., Smoot D.T., Ashktorab H., So J.B., Lim K.H., Yeoh K.G., Lim Y.P. ITIH3 is a potential biomarker for early detection of gastric cancer. J. Proteome Res. 2010, 9:3671-3679.
28. Jansen F.H., Krijgsveld J., van Rijswijk A., van den Bemd G.J., van den Berg M.S., van Weerden W.M., Willemsen R., Dekker L.J., Luider T.M., Jenster G. Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Mol. Cell Proteomics 2009, 8:1192-1205.
29. Tian J., Tang Z.Y., Ye S.L., Liu Y.K., Lin Z.Y., Chen J., Xue Q. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br. J. Cancer 1999, 81:814-821.
30. Yang B.W., Liang Y., Xia J.L., Sun H.C., Wang L., Zhang J.B., Tang Z.Y., Liu K.D., Chen J., Xue Q., Chen J., Gao D.M., Wu W.Z. Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice. Eur. J. Gastroenterol. Hepatol. 2008, 20:1077-1084.
31. Liang Y., Li W.W., Yang B.W., Tao Z.H., Sun H.C., Wang L., Xia J.L., Qin L.X., Tang Z.Y., Fan J., Wu W.Z. Aryl hydrocarbon receptor nuclear translocator is associated with tumor growth and progression of hepatocellular carcinoma. Int. J. Cancer 2011.
32. Jin G.Z., Li Y., Cong W.M., Yu H., Dong H., Shu H., Liu X.H., Yan G.Q., Zhang L., Zhang Y., Kang X.N., Guo K., Wang Z.D., Yang P.Y., Liu Y.K. ITRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma. J. Proteome Res. 2011, 10:3418-3428.
33. Handl J., Knowles J., Kell D.B. Computational cluster validation in post-genomic data analysis. Bioinformatics 2005, 21:3201-3212.
34. He Y., Wu X., Liu X., Yan G., Xu C. LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker. J. Proteome Res. 2010, 9:6180-6190.
35. Li Y., Tang Z.Y., Tian B., Ye S.L., Qin L.X., Xue Q., Sun R.X. Serum CYFRA 21-1 level reflects hepatocellular carcinoma metastasis: study in nude mice model and clinical patients. J. Cancer Res. Clin. Oncol. 2006, 132:515-520.
36. Aebersold R., Anderson L., Caprioli R., Druker B., Hartwell L., Smith R. Perspective: a program to improve protein biomarker discovery for cancer. J. Proteome Res. 2005, 4:1104-1109.
37. Hoffman R.M. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat. Rev. Cancer 2005, 5:796-806.
38. Perl A., Hanczko R., Telarico T., Oaks Z., Landas S. Oxidative stress inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol. Med. 2011.
39. Ma Y., Peng J., Huang L., Liu W., Zhang P., Qin H. Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis 2009, 30:2591-2599.
40. Hanczko R., Fernandez D.R., Doherty E., Qian Y., Vas G., Niland B., Telarico T., Garba A., Banerjee S., Middleton F.A., Barrett D., Barcza M., Banki K., Landas S.K., Perl A. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J. Clin. Invest 2009, 119:1546-1557.
41. Mann C.D., Neal C.P., Garcea G., Manson M.M., Dennison A.R., Berry D.P. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer 2007, 43:979-992.